Non-invasive prenatal testing – NIPT – has principally been restricted to a few specialized laboratories. There is an increasing demand however for a versatile and reliable NIPT test that allows clinical laboratories to implement and offer screening for the most common aneuploidies – trisomy of chromosome 21 (Down syndrome), 18 (Edwards syndrome) and 13 (Patau syndrome) – at their own facility.
Clarigo enables an optimal workflow for low to high throughput sample processing that further reduces the overall cost to a level that will make NIPT affordable for all pregnant women as an integral part of prenatal care.
The targeted design of Clarigo enables highly accurate trisomy calling of chromosomes 21, 18 and 13 based on only 2 M reads per sample, which is several times less than for shotgun approaches. Data analysis and interpretation is automated with the dedicated Clarigo™ Reporter software developed at Multiplicom and empowered by proprietary algorithms. The Clarigo Reporter further includes an intrinsic quality control assessment and provides information on the fetal fraction for each sample and optionally on fetal gender.